BSE · 544445
Asston Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹26 Cr with net profit ₹4 Cr — a 15.04% net margin, versus 8.59% the period before.
Shareholding
As of 2026-03-31
- Promoter50.66%
- Public47.42%
- FII1.91%
687 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.05× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #1 of 30 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,08,486 Cr | 277.41 | 12.42 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,077 Cr | 197.96 | 15.77 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,488 Cr | 67.81 | 13.07 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,366 Cr | 127.77 | 2.15 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,798 Cr | 68.79 | 2.45 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,559 Cr | 34.89 | 4.53 | 12.98% | 11.5% |
| Hikal Limited | ₹2,695 Cr | 186.8 | 2.25 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,242 Cr | 247.72 | 9.16 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 41.76 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,328 Cr | 67.76 | 3.19 | 17.67% | 13.66% |
| Asston Pharmaceuticals Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAsston Pharmaceuticals Limited (544445) last traded at a 52-week high of Rs 125.5 and a low of Rs 60. The company’s promoter holding was 50.6614% as of March 31, 2026. Debt-to-equity stands at 0.77. The latest annual revenue reported was Rs 25.6102 Cr in March 2025, with a net profit of Rs 3.8528 Cr and an EPS of 6.14.
Positives
- +Revenue increased from Rs 10.5546 Cr in March 2022 to Rs 25.6102 Cr in March 2025.
- +Net profit increased from Rs 0.1106 Cr in March 2022 to Rs 3.8528 Cr in March 2025.
- +Promoter holding at 50.6614% as of March 31, 2026, indicates a majority stake.
- +No promoter shares are reported as pledged.
Negatives
- −Promoter holding decreased from 69.0708% in January 2025 to 50.6614% in March 2026, representing a decrease of 18.41%.
- −FII holding decreased from 9.7035% in July 2025 to 1.9149% in March 2026.
- −No quarterly results have been disclosed.
Financial Performance
Asston Pharmaceuticals Limited's revenue increased to Rs 25.6102 Cr in March 2025, up from Rs 15.8409 Cr in March 2024. Net profit also rose to Rs 3.8528 Cr in March 2025, compared to Rs 1.3603 Cr in March 2024. Earnings per share (EPS) improved to 6.14 in March 2025 from 2.37 in March 2024, and EBITDA increased to 5.9657 in March 2025 from 2.7498 in March 2024.
Balance Sheet
The company's debt-to-equity ratio is 0.77. Further details regarding assets, liabilities, and other balance sheet components are not available in the provided data.
Ownership & Pledges
As of March 31, 2026, promoters held 50.6614% of the company's shares. Public shareholding was 47.4237%, while FIIs held 1.9149%. There were no promoter pledges reported. The number of shareholders increased from 104 in January 2025 to 687 in March 2026.
Regulatory & Surveillance
The company is not currently under any surveillance measures according to the provided data. There is no information available regarding specific regulatory actions or compliances.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Asston Pharmaceuticals Limitedshare price & fundamentals